First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Titel:
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Auteur:
Fay, Andre P Fizazi, Karim Matsubara, Nobuaki Azad, Arun A Saad, Fred De Giorgi, Ugo Joung, Jae Young Fong, Peter C C Jones, Robert J Zschäbitz, Stefanie Oldenburg, Jan Shore, Neal D Dunshee, Curtis Carles, Joan Cislo, Paul Chang, Jane Healy, Cynthia G Niyazov, Alexander Agarwal, Neeraj